CU Innovations continues to redefine the future of patient care through a dynamic blend of translational science, venture development, and strategic partnerships. The 2025 Annual Report highlights a year of bold initiatives and measurable impact, as CU Anschutz researchers and startup collaborators advanced therapies, reshaped clinical trial design, and accelerated commercialization across the biomedical landscape.
This year, CU Innovations launched the Healthcare Innovation & Entrepreneurship (HIE) Initiative, a campus-wide effort to empower faculty innovators with mentorship, education, and funding. The initiative reflects CU Anschutz’s commitment to cultivating a collaborative ecosystem where discovery meets impact.
The expansion of the Data 2.0 strategy further positioned CU Innovations at the forefront of data-driven drug development and precision medicine. By integrating advanced analytics and real-world evidence, CU researchers are unlocking new pathways to personalized care.
Among the standout startups featured in the report are:
These ventures not only secured significant capital and licensing deals but also demonstrated real-world patient impact across diverse therapeutic areas.
CU Innovations also celebrated internal growth, with new fellows contributing to translational science and commercialization efforts. The team’s expanded capabilities reflect a strategic investment in the future of biomedical innovation.
As CU Innovations continues to unite industry partners, entrepreneurs, and investors, the 2025 report underscores a shared mission: to accelerate discoveries that improve lives—locally and globally.